Drug Profile
ONO 2160/carbidopa
Alternative Names: Carbidopa/levodopa prodrug; Carbidopa/ONO-2160; Levodopa prodrug/carbidopaLatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Parkinson's-disease in Japan (PO, Tablet)
- 19 Apr 2016 Phase-I development is ongoing in Japan
- 30 Nov 2014 Ono Pharmaceuticals completes enrolment in its phase I trial for Parkinson's disease in Japan (PO) after November 2014 (JapicCTI142702)